Fortive FTV
Technology · Hardware, Equipment & Parts · Synthos Deep Dive · 2026-07-03
The Overview
Fortive owns a collection of specialized industrial and healthcare brands — think Fluke electrical testers, Industrial Scientific gas detectors, Accruent and ServiceChannel facilities software, and ASP/STERRAD hospital sterilization systems. It sells the "picks and shovels" that factories, hospitals, and utilities need to run safely. In mid-2025 it split off its Precision Technologies arm (Tektronix, sensors, etc.) into a separate company called Ralliant, so what's left is smaller but higher-margin and more software-heavy.
The business is genuinely good — very profitable, steady, well-run. But the stock is fairly priced, not cheap: you're paying about 21 times next year's expected earnings for a company growing sales only about 5% a year. That's a fine price for a fine business, but it doesn't leave much room for a mistake or for big gains. Our verdict is Watch — a solid company worth owning at a better price, but not a bargain today.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The stock is calm (it doesn't swing much) and the company pays its bills fine, but the price already assumes everything keeps going right, and it carries a moderate debt load.
- Growth Quality 5/10 (solid, not spectacular). High margins and a disciplined operating system, but sales are only crawling forward.
- Exponential Potential 3/10 (low). This is a steady grower in mature markets, not a rocket ship. Don't expect it to double quickly.
The one big worry: if growth stays this slow, the stock's above-average price tag could shrink back toward the market average — meaning the shares could fall even if the business does fine.
Putting a number on it: our fair-value estimate is $62 against a current price of $59.69 — real upside if our numbers are right.
Our summary metrics
Low beta (0.98) & serviceable leverage, but 37× trailing / 21× fwd on a mid-single-digit grower with 2.6× net-debt/EBITDA.
Post-spin pure-play with 62% gross margin & 29% adj-EBITDA margin, but only ~5% core revenue and high-single-digit EPS CAGR.
A stable FBS compounder, not an exponential — flattish revenue estimates, $19B cap, mature end-markets. Room-to-run is limited.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A stable FBS compounder, not an exponential — flattish revenue estimates, $19B cap, mature end-markets. Room-to-run is limited.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $63.29 (high $70 / low $51; 11 Buy · 17 Hold · 2 Sell → Hold) — context, not our anchor |
| Valuation | 37× trailing EPS · 21× FY26E · 19× FY27E · 15× FY30E · EV/S 4.7× · EV/EBITDA 18.2× |
| Technicals | Uptrend — $62.65, −0.2% off 52-wk high, above 50/200-DMA, RSI 65, +17.9% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices in the Synthos KB; this call rests entirely on fundamentals + quant |
| Position sizing | Satellite / quality-industrial sleeve, ≤2–3% if bought — and only on a pullback |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for FTV — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $59.69, 2% below the 50-day average ($61), 3% above the 200-day average ($58) — a mixed trend. 7% below the 52-week high of $64, 27% above the 52-week low of $47.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $59.69 is currently inside the band (band $59–$62).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 45.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.07, negative momentum.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = FTV · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Fortive Corporation (NYSE: FTV) is a global industrial-technology company spun out of Danaher in 2016, headquartered in Everett, Washington, and run on the Danaher-style "Fortive Business System" (FBS) of continuous operational improvement. The defining recent event: on June 28, 2025 Fortive completed the spin-off of its Precision Technologies segment as an independent company, Ralliant Corporation. As a result, FY2025 is reported on a continuing-operations basis and the company now runs two segments instead of three. Fiscal year ends late December.
- Intelligent Operating Solutions (IOS) — equipment reliability tools (Fluke), EHSQ/compliance software (Intelex), facilities and asset-lifecycle software (Accruent, Gordian, ServiceChannel), and gas detection (Industrial Scientific). This is the software-and-instruments engine.
- Advanced Healthcare Solutions (AHS) — sterilization and instrument reprocessing (ASP/STERRAD), surgical-instrument tracking (Censis/Censitrac), biomedical test tools (Fluke Biomedical), and radiation-safety monitoring (Landauer, RaySafe).
Revenue mix (FY2025 continuing operations, from filings):
- By segment: Intelligent Operating Solutions $2.86B (69%) · Advanced Healthcare Solutions $1.30B (31%). (These two total ~$4.16B; the $5.14B FY25 continuing-ops revenue line includes stub/other and timing items around the mid-year separation — treat FY25 as a transition year.)
- By geography (last full pre-spin disclosure, FY2024): United States $3.37B (54%) · countries ex-US & China $2.21B (36%) · China $0.65B (10%). A majority-US, developed-market revenue base with meaningful China exposure (a tariff/trade-policy risk flagged in management's own filing).
The strategic story management is selling is "Fortive Accelerated" — a post-spin, three-pillar plan (organic-growth acceleration via "FBS Amplified," disciplined capital allocation, and rebuilding investor trust). It is a sharpen-the-portfolio story, not a hypergrowth one.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of FTV in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0. No investor, podcast, or analyst voice in our distilled KB has taken a position on Fortive, so there is no claim_id to cite — and we do not fabricate one.
That means this note carries no conviction-panel signal, and the verdict rests entirely on the fundamentals, the analyst estimates, the valuation, and the quant/technical picture below. Read it that way: the absence of expert breadth is itself a reason the conviction rating is Low and the verdict is Watch rather than a higher-conviction Buy. Where I use management's words (§9), they are explicitly half-weighted as a self-interested source.
For external context only (not Synthos KB claims): the sell-side consensus is Hold — 11 Buy, 17 Hold, 2 Sell — with a $63.29 average target essentially on top of the current $62.65 price. The Street, too, sees this as fairly valued.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.98, low drawdown, and interest coverage ~7× make it sturdy — but 37× trailing / 21× forward on a ~5% grower with net-debt/EBITDA 2.6× leaves real de-rating risk. |
| Growth Quality | 5 · Solid | 62% gross margin, 29% adj-EBITDA margin, FBS operational rigor and recurring software — but only ~5% core revenue growth and high-single-digit EPS CAGR, with ROIC in the ~7% range and 81% of assets in goodwill/intangibles. |
| Exponential Potential | 3 · Low | Flattish revenue estimates, mature safety/test/healthcare end-markets, and a $19B cap in served markets that are large but slow. A compounder, not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | FBS Amplified re-accelerates organic growth to high-single digits; buybacks (already $1.8B in three quarters) shrink the share count; AHS margin expansion continues. FY27E EPS beats to ~$3.45 (vs $3.22 cons); market pays up ~22.5×. | ~$78 (+25%) |
| Base (our anchor) | Estimates roughly hit — FY26E EPS $2.99 → FY27E $3.22; a steady ~5% grower with 62% GM holds a ~20× forward multiple. | ~$62 (−1%) |
| Bear | Industrial demand softens, China/tariff drag bites, growth stalls near flat; the premium multiple compresses toward the market as the "spin re-rating" fails to show up. FY27E EPS misses to ~$2.90; multiple de-rates to ~16×. | ~$46 (−27%) |
Synthos fair value = the base case, ~$62 (≈flat vs $62.65), with the full $46–$78 span as the honest range. This anchor sits essentially on top of the Street's $63.29 consensus — an unusually tight agreement that reflects a genuinely fairly-priced stock rather than a mispricing. This is a tracked call — the Forecaster Scorecard grades it once it matures. The message is not "avoid," it is "the price already reflects the quality; wait for a better entry."
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). FTV is a decent compounder with distinctly low exponential potential:
- Forward growth: on the continuing-ops estimate base, revenue is roughly flat-to-slightly-up ($4.33B FY26E → $5.09B FY30E, ~4% CAGR, partly a low-base artifact of the spin) and EPS CAGR is ~8.7% (FY26E $2.99 → FY30E $4.17). Management's own core-revenue print is ~5%.
- Acceleration (the 2nd derivative) is roughly flat, not positive: EPS steps of $2.99 → $3.22 → $3.48 → (…) → $4.17 are a steady high-single-digit grind, not an inflection. There is no evidence of accelerating growth in the numbers.
- Room to run: the safety, electrical-test, facilities-software, and hospital-sterilization markets are large but mature and slow-growing. At a $19B cap the issue is not law-of-large-numbers so much as slow underlying market growth — the TAM does not compound fast enough to power a multibagger.
- Reinvestment runway: capital allocation is tilted toward buybacks and bolt-on M&A (the Danaher playbook) rather than a high-return organic reinvestment wave. That supports EPS but caps the exponential upside.
Exponential Potential: Low (3/10). Own it — if at all — for steady high-single-digit earnings compounding plus buybacks, not for a fast re-rating or a multibagger. A small, accelerating name would score far higher here; FTV honestly does not.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 continuing-ops $5.14B (vs $6.23B FY24 on the old three-segment basis — the difference is the Ralliant spin). On a like-for-like core basis management reported ~5% growth.
- Quarterly trajectory (post-spin, continuing ops): the clean read is Q1'26 $1.069B, +7.7% reported / +5.3% core YoY — a solid start with a ~150bp selling-days tailwind.
- Margins: gross 61.8% TTM, adjusted-EBITDA ~29% (management's Q1'26 figure), operating ~17–18%, net 11.5% TTM. High-quality margins for an industrial — the software and healthcare mix shows.
- Earnings: FY25 continuing-ops net income ~$641M (GAAP net $579M after a −$62M discontinued-ops item); GAAP diluted EPS $1.74. Q1'26 GAAP EPS $0.44 (+33% YoY), adjusted EPS $0.70 (+25% YoY).
- Cash flow: FY25 operating CF $1.08B, capex ~−$105M, FCF ~$978M (FCF yield ~5.1%). Q1'26 FCF $194M. Cash conversion is strong — a hallmark of the FBS model.
- Balance sheet: total debt $3.21B, cash $376M, net debt ~$2.83B, net-debt/EBITDA ~2.56× (TTM). Investment-grade and serviceable (interest coverage ~7×), but not a fortress — leverage is the main balance-sheet caveat, elevated partly by post-spin capital moves and $1.8B of buybacks in three quarters. Goodwill + intangibles are 81% of total assets, a reminder this is an acquisition-built portfolio.
6. Valuation — priced in or room?
FTV is fairly valued, leaning full. Trailing metrics: 37× GAAP EPS, 4.7× EV/sales, 18.2× EV/EBITDA. Forward metrics on live consensus: 21× FY26E ($2.99) → 19× FY27E ($3.22) → 15× FY30E ($4.17) — the multiple compresses as EPS grinds higher, but only because the starting point is rich for the growth rate. FCF yield ~5.1% and earnings yield ~2.8% are unremarkable for a slow grower.
The bull's defense is that a 62%-gross-margin, high-cash-conversion, FBS-run pure-play deserves a premium industrial multiple, and that buybacks compound EPS faster than revenue. Fair. But at ~21× forward for ~5% core growth, the PEG-style math is stretched (FMP's forward PEG reads ~4.9×), and there is little margin for a demand or execution stumble. Street targets (context): consensus $63.29, high $70, low $51 — and our ~$62 base fair value lands right in the middle. This is the rare case where our model and the Street essentially agree: not cheap, not egregious — fairly priced. That is precisely why the verdict is Watch, not Buy.
7. Technicals (from the tech block)
- Trend: up. $62.65 sits above the 50-DMA ($60.42) and 200-DMA ($55.60), with the 50 above the 200 (golden-cross posture). MACD +0.47 (mildly positive).
- Location: essentially at the 52-week high (−0.2% from $62.78), +34.6% off the 52-week low ($46.55) — a leadership posture with a shallow max drawdown (−3.7% from peak).
- Momentum: RSI(14) 65 — strong but not yet overbought (<70). Buying right at a 52-week high with RSI in the mid-60s is a stretched-entry caution, not a red flag.
- Relative strength: FTV +17.9% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged both the market and the Nasdaq over the past year, though it has roughly matched SPY over 3 months (+12.1% vs +13.7%). Not a relative-strength leader.
- Read: technicals are constructive but do not scream buy — the stock is at highs after a run, RSI is elevated, and it has trailed the index. A pullback toward the rising 50-DMA (~$60) or 200-DMA (~$56) would be a materially lower-risk entry than chasing the 52-week high.
8. Moat & competitive position
Fortive's moat is moderate and durable rather than wide: (1) installed-base and switching costs — Fluke test tools, ASP/STERRAD sterilizers, and Accruent/ServiceChannel facilities software are embedded in customer workflows with recurring software, service, and consumable revenue; (2) brand and regulatory positioning — iconic "inventor brands" with leading share in fragmented niches, and healthcare products with regulatory qualification barriers; (3) the Fortive Business System — a genuine operational-execution edge inherited from Danaher. The limits: end-markets are mature and cyclical-adjacent (industrial, utilities, electronics, healthcare capex), and growth leans on bolt-on M&A. Post-spin, the portfolio is higher-quality and more software/healthcare-weighted than before — a real positive.
Peer set (FMP-supplied, market cap): Coherent $52.9B, Corpay $23.0B, F5 $23.0B, Fabrinet $17.9B, GoDaddy $11.7B, Gen Digital $16.1B, CGI $14.4B, Gartner $9.1B, Logitech $13.5B, Trimble $12.4B. (Note: this FMP peer list skews toward tech/software rather than pure diversified-industrial comps like Roper, Ametek, Dover, or Danaher itself — the more natural valuation peers. Read the list as "quality-compounder tech-industrials," and judge FTV's ~21× forward multiple against that mixed group with that caveat.) FTV's growth and multiple sit mid-pack; nothing here argues it is a standout bargain.
9. Management, capital allocation & guidance
- Leadership: President & CEO Olumide Soroye (relatively new, driving the "Fortive Accelerated" post-spin strategy). ~10,000 employees across ~50 countries.
- Capital allocation: buyback-forward — $500M repurchased in Q1'26 (≈9M shares, ~3% of diluted shares), $1.8B across the three quarters since the "new Fortive" launched. Plus a modest dividend ($0.24/yr, ~0.4% yield, ~15% payout). Bolt-on M&A remains part of the model. This is EPS-supportive but underscores the point that growth is being manufactured partly through the share count, not just the top line.
- Insider activity: the recent Form 4 cluster (filed 2026-06-11) is routine annual director equity awards (A-Award grants of ~3,350 shares each), not open-market buying or discretionary selling. No signal either way.
- Management's own guidance (half-weighted — they talk their book): From the Q1'26 earnings release (SEC 8-K, filed 2026-04-30), management reaffirmed FY2026 adjusted diluted EPS guidance of $2.90–$3.00 and said it is "currently trending toward the upper half of the range." They reported Q1'26 core revenue +5%, adjusted EBITDA +13%, and adjusted EPS +25%, and described the "Fortive Accelerated" medium-term framework as "solidly intact." This is a real earnings release with genuine forward guidance — but it is management's self-interested framing and is weighted accordingly. The upper-half FY26 adj-EPS ($~2.95–3.00) is consistent with the $2.99 consensus our base case uses.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $0.69, revenue ~$1.07B). The key lines: core organic growth (does FBS Amplified push it above ~5%?) and whether FY26 guidance moves to the upper half or above.
- Organic-growth re-acceleration: the entire bull case is that "Fortive Accelerated" lifts core growth into the high-single digits. Watch two consecutive quarters of accelerating core growth as confirmation.
- AHS margin expansion: healthcare-segment adjusted-EBITDA margin was +210bps YoY in Q1'26 — continued gains would support the premium multiple.
- Buyback pace & leverage: whether management keeps repurchasing at ~$500M/quarter while holding net-debt/EBITDA near/below ~2.5×.
- Macro/China/tariffs: management explicitly flags trade policy and China exposure as risks — a demand or tariff shock is the main external swing factor.
Thesis tripwires (what would change the call): core organic growth stalling toward flat; FY26 guidance cut; net-debt/EBITDA rising materially above ~3×; or the multiple staying >22× forward without any growth re-acceleration (a signal to trim, not add).
11. Key risks
- Valuation / de-rating (primary): 37× trailing / 21× forward for ~5% core growth. If the post-spin re-rating thesis doesn't deliver faster growth, the premium multiple can compress toward the market — the stock could fall even if the business is fine.
- Slow, mature end-markets: industrial test, safety, facilities, and healthcare capex grow slowly and are cyclical-adjacent; a downturn pressures the most economically-sensitive lines.
- Leverage: net-debt/EBITDA ~2.6× is manageable but not conservative, and aggressive buybacks ($1.8B in three quarters) leave less balance-sheet cushion than a lower-levered peer.
- China / trade policy: ~10% of pre-spin revenue is China; management's own filing flags tariffs and "responsive economic nationalism" as material risks.
- Execution / integration: the model depends on continued FBS-driven margin gains and successful bolt-on M&A; a stumble in either undercuts the quality premium.
- No expert corroboration: unlike our conviction-track names, there is zero independent expert breadth in the Synthos KB to cross-check the fundamentals — a lower-information setup that argues for humility and a Watch stance.
12. Verdict, position sizing & monitoring
Watch. Fortive is a genuinely good, higher-quality-post-spin industrial-technology compounder — 62% gross margins, ~29% adjusted-EBITDA margins, strong cash conversion, and a disciplined operating system. But it trades at ~21× forward earnings for only mid-single-digit core growth, its fair value (~$62) sits right on the current price and the Street's $63.29 consensus, and there is no expert conviction in the Synthos KB to tip the scales. That combination — good company, full price, modest growth, low information breadth — is the textbook definition of a Watch, not a Buy.
- Sizing (if bought): a satellite/quality-industrial position, ≤2–3%, and only on a pullback toward the 50-DMA (~$60) or 200-DMA (~$56) to improve the entry. Chasing the 52-week high at 21× forward is the low-reward move.
- Upgrade trigger: two consecutive quarters of accelerating core organic growth (toward high-single digits) and/or a de-rate to ~17–18× forward would move this toward Buy — Tactical. A guidance cut or growth stall moves it toward Avoid.
- Monitoring: re-underwrite each earnings print (next 2026-07-29); formal re-score on any change in growth trajectory or leverage. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $62.65.
- Single biggest risk: multiple de-rating — the price already assumes flawless FBS execution and a growth re-acceleration that the numbers do not yet show.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of FTV in the Synthos knowledge base, so no
claim_idis cited and none is fabricated. This note is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-04-03 (Q1'26 continuing operations) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates. Note the Precision Technologies (Ralliant) spin-off (June 28, 2025) breaks year-over-year comparability — FY2025+ figures are continuing operations.
- Management caveat: the FY2026 adjusted-EPS guidance ($2.90–$3.00, trending upper half) is management's own book, half-weighted by design.
- Peer-set caveat: the FMP peer list skews to tech/software; the more natural diversified-industrial comps (Roper, Ametek, Dover, Danaher) are not in it.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").